News

Fierce Pharma4h
Merck KGaA springs back into M&A game with $3.9B buyout of Pfizer spinout SpringWorks
Merck KGaA’s long courtship of SpringWorks Therapeutics has come to fruition as the German drugmaker has bought out the ...
STAT3d
Akeso wins Chinese approval for cancer drug positioned to rival Merck’s Keytruda
Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this ...
Merck lowers profit outlook, partly due to $200 million expected tariff hit
Merck said the expected tariff charge primarily reflects levies between the U.S. and China, but does not account for Trump’s planned pharmaceutical tariffs.
Fierce Pharma2h
AACR: Merck's Keytruda prevents head and neck cancer from returning in industry-first win
Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain ...
These Stocks Are Moving the Most Today: Tesla, Domino’s, Nvidia, Merck, Spirit AeroSystems, Meta, and More
Domino’s Pizza reports earnings, Nvidia faces stiff competition in China, and Spirit AeroSystems finalizes a deal to transfer ...
2 Must-Own Dividends At Bargain Basement Prices
Discover April's top dividend bargains! Explore high-quality blue-chip stocks like Merck & Schlumberger with strong yields, ...
Morningstar15h
Germany's Merck to Buy SpringWorks for $3.9 Billion — Update
Germany's Merck KGaA agreed to acquire U.S. biopharmaceutical company SpringWorks Therapeutics for around $3.9 billion, in a bid to expand its oncology and rare disease business. The German ...
Halozyme sues Merck; FDA blames cuts for Vanda delay
Halozyme claims Merck infringed on patents in developing a subcutaneous form of Keytruda. Elsewhere, Vanda’s challenge to an ...